D. E. Shaw & Co., Inc. Citius Pharmaceuticals, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding CTXR
# of Institutions
73Shares Held
30.6MCall Options Held
24.7KPut Options Held
0-
Armistice Capital, LLC New York, NY10.2MShares$4.37 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$2.72 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$881,0090.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$776,4620.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.65MShares$707,9070.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $62.8M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...